|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Tracking Information | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | September 9, 2005 | ||||||||||||||||
| Last Updated Date | September 9, 2005 | ||||||||||||||||
| Start Date ICMJE | July 2002 | ||||||||||||||||
| Primary Completion Date | |||||||||||||||||
| Current Primary Outcome Measures ICMJE |
|
||||||||||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||
| Change History | No Changes Posted | ||||||||||||||||
| Current Secondary Outcome Measures ICMJE |
|
||||||||||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||
| Descriptive Information | |||||||||||||||||
| Brief Title ICMJE | Impact of Insecticide-Treated Curtains on Antimalarial Drug Resistance | ||||||||||||||||
| Official Title ICMJE | A Study of the Impact of Insecticide-Treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso | ||||||||||||||||
| Brief Summary | Attempts to understand the relationship malaria transmission intensity and antimalarial drug resistance had rested mainly on mathematical models. To date, except for two studies which reported reductions in the prevalence of drug resistance in Tanzania and Zimbabwe, no other field data addressed the impact of reducing malaria transmission by the use of vector control measures on antimalarial drug resistance. Thus whether vector control decrease or increase drug resistance remains a contentious issue. The aim of this study was to investigate the impact of insecticide-treated curtains (ITCs) on clinical and parasitological outcomes in children with uncomplicated malaria treated with chloroquine (CQ), on the prevalence of genetic markers of resistance to CQ and sulphadoxine-pyrimethamine (SP) and on the ability of children to clear drug resistant parasites. The therapeutic efficacy of CQ was studied in 9 villages which used ITCs for 6-8 years and 9 villages with no history of ITC use. A cross-sectional survey was also conducted to estimate the prevalence of genetic markers of resistance to CQ and SP in asymptomatic children. |
||||||||||||||||
| Detailed Description |
3.1 Field work Passive case detection was used to recruit children aged 6-59 months with uncomplicated malaria using a slightly modified version of the standard WHO in vivo method for assessing therapeutic efficacy of anti-malarial drugs .Children seeking care at the selected health centres were screened for eligibility to join the study, enrolled and followed up for 14 days. If a child’s axillary temperature was >=37.5 ºC and no obvious cause of fever other than malaria was found on clinical examination, about 500 ml of blood was drawn into a micro-container containing EDTA. Microscopic diagnosis of malaria and measurement of packed-cell volume (PCV) were performed immediately after samples were received in the laboratory. After enrolment, further clinical examinations were performed on days 1, 2, 3, 7, and 14. In addition, the caretakers were advised to bring children back to the health centre at any time between day 1 and day 14 if the child’s condition did not improve. Thick and thin blood films and filter paper blood spots were prepared on days 0, 3, 7, 14 and at unscheduled visits. Treatment of children and treatment outcome A standard treatment with CQ was administered to children with uncomplicated malaria. The treatment dosing was 25 mg/kg body weight of CQ over 3 days; 10 mg/kg on days 0, 1 and 5 mg/kg on day 2. Treatment was administered at the clinic under the supervision of a nurse. Outcomes for the in vivo trial were classified according to the WHO clinical and parasitological assessment system Prevalence of pfcrt-76 and pfmdr1-86 mutations in the community A cross-sectional survey was conducted to estimate the prevalence of pfcrt-76 and pfmdr1-86 mutations in asymptomatic children. Random samples of children aged 6 to 59 months and children aged 5 years to 14 years were selected per village. Thick and thin blood films and filter paper blood spots were prepared from a finger-prick. Estimation of the entomological inoculation rate A cross-sectional survey was conducted at the peak period of malaria transmission (September 2002) for the estimation of the EIR. Catches were performed using CDC light traps. An ELISA test was used to detect the presence of P. falciparum circumsporozoite protein (CSP). Socio-economic and health seeking behaviour survey In 2003, a survey was performed in a random sample of 20 compounds in each village to collect data on health seeking behaviour, socio-economic and demographic features of the study population including the frequencies of population movements between villages. 3.2 Laboratory methods Thick and thin blood films were stained with Giemsa stain (3%) for 45 minutes. Asexual parasites and gametocytes of P. falciparum were counted against 400 white blood cells. For molecular biology analyses, DNA was extracted from pre, post-treatment and cross-sectional survey filter paper blood spots using chelex. DNA was amplified by nested PCR to detect mutations at pfcrt-76. Nest 2 PCR products were digested by Apo I endonuclease restriction enzyme and electrophoresed onto a 3% agarose. Sequence-specific oligonucleotide probing (SSOP) was performed to detect the presence of pfmdr1-86 mutation. Mutations at dhfr (51, 59 and 108) and at dhps ( 437 and 540) were also detected by SSOP. MSP2 gene polymorphisms were studied by PCR to differentiate recrudescence from new infections. 3.3 Sample size and power With 18 communities (9 per group), the study would have 80% power to detect, at the 5% significance level, a 50% decrease in clinical failure rate in eligible children. This number of communities would also permit the detection of a 40% decrease in parasitological failure rate in eligible children with the same power, and at least 60% and 40% increases in clinical and parasitological failure rates, at 5% significance level, in children carrying parasites with CQ resistant genotypes before CQ treatment was started. 3.4 Data processing and analyses Two data clerks independently entered data onto computers using EPIINFO version 6.0. Analyses were performed using STATA (Release 8.2, www.stata.com). The study main endpoints were examined using Generalized Estimating Equations regression model 3.5 Community approval This was obtained after meetings with community leaders to explain the objectives of the study and what it involved. In addition to community consent, individual signed informed consent was obtained from caretakers of children before enrolment. |
||||||||||||||||
| Study Phase | |||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||
| Study Design ICMJE | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study | ||||||||||||||||
| Condition ICMJE | Malaria | ||||||||||||||||
| Intervention ICMJE | Drug: Chloroquine | ||||||||||||||||
| Study Arms / Comparison Groups | |||||||||||||||||
| Publications * | |||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||||||||||
| Recruitment Information | |||||||||||||||||
| Recruitment Status ICMJE | Completed | ||||||||||||||||
| Enrollment ICMJE | 1035 | ||||||||||||||||
| Completion Date | December 2002 | ||||||||||||||||
| Primary Completion Date | |||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria: Age between 6 and 59 months Mono infection with P.falciparum malaria, with parasitaemia in the range of 1,000 to 150,000 parasites per ml Absence of danger signs or signs of severe malaria. Axillary temperature >= 37.5 ºC. Absence of signs of severe malnutrition. Absence of any obvious cause of fever other than malaria. No history of allergy to CQ. Willingness to return to the health facility for follow-up. Informed consent obtained from the caretaker of the child Exclusion Criteria: Danger signs of severe or complicated malaria, persisted vomiting. Received treatment with an antimalarial drug other than CQ in the last 2 weeks. Caretaker did not sign the consent form |
||||||||||||||||
| Gender | Both | ||||||||||||||||
| Ages | 6 Months to 59 Months | ||||||||||||||||
| Accepts Healthy Volunteers | No | ||||||||||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||
| Location Countries ICMJE | Burkina Faso | ||||||||||||||||
| Administrative Information | |||||||||||||||||
| NCT ID ICMJE | NCT00169078 | ||||||||||||||||
| Responsible Party | |||||||||||||||||
| Study ID Numbers ICMJE | ITCR5093 | ||||||||||||||||
| Study Sponsor ICMJE | Gates Malaria Partnership | ||||||||||||||||
| Collaborators ICMJE | |||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||
| Information Provided By | Gates Malaria Partnership | ||||||||||||||||
| Verification Date | September 2005 | ||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||